Clinical Practice

The NICE Decision Support Unit and EEPRU have released updated Stata, Excel and R commands for mapping EQ-5D-3L data to the new EQ-5D-5L value set, giving UK HTA analysts a validated route to convert legacy three-level utility data ahead of NICE's adoption of the five-level value set.

Why has Portugal's Ordem dos Médicos welcomed the SINACC postponement? The medical association says the surgery access system was still in testing and lacked safeguards, warning that reclassifying minor surgery could hide patients from waiting lists. Read what 278,394 patients on the list means for the rollout. #SyenzaNews #HealthEconomics #digitalhealth #healthcarepolicy

How are cell therapies redefining cancer care through rigorous HTA evaluation? INCA’s latest analysis highlights how CAR-T and other advanced cell therapies are shifting oncology paradigms—balancing innovation with evidence-based access and cost-effectiveness. Explore the full breakdown and its implications for global cancer treatment. #SyenzaNews #oncology #precisionmedicine #innovation #MarketAccess

💊 Is it safe to stop statins in elderly patients for primary prevention? A recent trial shows that deprescribing statins in older adults without established cardiovascular disease does not increase the risk of adverse outcomes, supporting more individualized prescribing decisions. Discover the full trial results and implications for clinical practice. #SyenzaNews #clinicaltrials #pharmaceuticals #costeffectiveness #healthcarepolicy

Is tirzepatide delivering better value than semaglutide for patients and payers? A fresh analysis shows how tirzepatide can drive greater cost savings alongside improved health outcomes in obesity and type 2 diabetes management. Discover the key findings shaping treatment and reimbursement decisions. #SyenzaNews #pharmaceuticals #HealthEconomics #costeffectiveness

🚀 What if the first oral GLP-1 therapy just cleared its biggest regulatory hurdle in Europe? The MHRA has approved orforglipron, delivering the continent’s first oral win and offering patients a convenient, needle-free option for weight management and type 2 diabetes. Read the full story on this landmark approval. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

🔍 How does the FDA’s complete response letter change the game when it isolates manufacturing concerns? By focusing solely on production issues, the agency has clarified a potential approval pathway once these hurdles are addressed—offering new insights for drug developers. Discover the implications for regulatory strategy and timelines. #SyenzaNews #regulatoryaffairs #pharmaceuticals #innovation

What if blending ICU clinician models delivers the best patient outcomes? A new analysis comparing staffing approaches reveals that hybrid models—merging physician-led oversight with advanced practice provider expertise—outperform traditional structures in efficiency, cost, and care quality. Explore the full findings and see how this evidence can guide your ICU strategy. #SyenzaNews #healthcare #HealthcareInnovation #innovation #strategicplanning

How can statutory health insurance reforms put prevention at the center of care? New updates prioritize proactive health measures to improve outcomes, reduce long-term costs, and strengthen system sustainability. Explore the key changes reshaping healthcare policy. #SyenzaNews #healthcare #HealthcareInnovation #healthcarepolicy #innovation

📉 Disappointing results from the SION-719 cystic fibrosis trial – what does this mean for future drug development? The study failed to meet key endpoints, underscoring ongoing challenges in advancing new therapies for CF patients. Read the full breakdown of the findings and their implications. #SyenzaNews #clinicaltrials #drugdevelopment #innovation #MarketAccess

Is the PRIME scheme growing more exclusive for innovative medicines? Eligibility criteria for the European Medicines Agency’s PRIME scheme remain highly selective in 2026, underscoring the rigorous standards required to secure early regulatory support for therapies addressing unmet medical needs. Discover what this means for drug developers and patients. #SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #MarketAccess

Portugal's INFARMED has blocked public funding for Datroway in breast cancer, citing insufficient added value.